Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
SARS-CoV-2 Omicron subvariants have generated a worldwide health crisis due to
resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of …
resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of …
Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
Z Ling, C Yi, X Sun, Z Yang, B Sun - Science China Life Sciences, 2023 - Springer
Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been
approved in many countries, with most being developed based on the original strain of …
approved in many countries, with most being developed based on the original strain of …
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation
JP Dowling, PA Nikitin, F Shen, H Shukla, JP Finn… - MAbs, 2023 - Taylor & Francis
Immune checkpoint inhibitors that overcome T cell suppressive mechanisms in tumors have
revolutionized the treatment of cancer but are only efficacious in a small subset of patients …
revolutionized the treatment of cancer but are only efficacious in a small subset of patients …
Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants
H Guo, Y Yang, T Zhao, Y Lu, Y Gao, T Li… - Communications …, 2023 - nature.com
Due to the continuous evolution of SARS-CoV-2, the Omicron variant has emerged and
exhibits severe immune evasion. The high number of mutations at key antigenic sites on the …
exhibits severe immune evasion. The high number of mutations at key antigenic sites on the …
Broad Epitope Coverage of Therapeutic Multi-Antibody Combinations Targeting SARS-CoV-2 Boosts In Vivo Protection and Neutralization Potency to Corner an …
I Roodink, M van Erp, A Li, S Potter… - Biomedicines, 2024 - mdpi.com
Therapeutic antibodies (Abs) which act on a broader range of epitopes may provide more
durable protection against the genetic drift of a target, typical of viruses or tumors. When …
durable protection against the genetic drift of a target, typical of viruses or tumors. When …
Potential use of the S-protein–Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019
L Feng, S Fu, P Zhang, Y Zhang, Y Zhao… - Frontiers in Public …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes
coronavirus disease 2019 (COVID-19), infects humans through a strong interaction between …
coronavirus disease 2019 (COVID-19), infects humans through a strong interaction between …
Development of a Single-Chain Fragment Variable that Binds to the SARS-CoV-2 Spike Protein Produced by Genetically Modified Lactic Acid Bacteria
SARS-CoV-2 enters cells via binding of the surface-exposed spike protein RBD to host cell
ACE2 receptors. Therefore, in this study, we designed a scFv (single-chain fragment …
ACE2 receptors. Therefore, in this study, we designed a scFv (single-chain fragment …
Towards a structural and functional analysis of the immunoglobulin-fold proteome.
C Tawfeeq, J Song, U Khaniya, T Madej… - Advances in Protein …, 2024 - europepmc.org
The immunoglobulin fold (Ig fold) domain is a super-secondary structural motif consisting of
a sandwich with two layers of β-sheets that is present in many proteins with very diverse …
a sandwich with two layers of β-sheets that is present in many proteins with very diverse …